D.E. Shaw & Co
TNGX icon

D.E. Shaw & Co’s Tango Therapeutics TNGX Stock Holding History

D.E. Shaw & Co’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,025,553
Closed -$9.09M – 5066
2025
Q4 		$9.09M Buy
1,025,553
+595,174
+138% +$5.13M 0.01% 1849
2025
Q3 		$3.62M Buy
+430,379
New +$2.91M ﹤0.01% 2500
2025
Q2 		– Sell
-68,269
Closed -$93.5K – 4716
2025
Q1 		$93.5K Sell
68,269
-46,558
-41% -$114K ﹤0.01% 4027
2024
Q4 		$355K Buy
+114,827
New +$533K ﹤0.01% 3807
2024
Q1 		– Sell
-15,413
Closed -$153K – 4745
2023
Q4 		$153K Buy
+15,413
New +$134K ﹤0.01% 3922
2023
Q1 		– Sell
-30,404
Closed -$220K – 4865
2022
Q4 		$220K Sell
30,404
-74,487
-71% -$524K ﹤0.01% 4209
2022
Q3 		$380K Sell
104,891
-72,525
-41% -$310K ﹤0.01% 4203
2022
Q2 		$804K Buy
+177,416
New +$1.07M ﹤0.01% 3774

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

D.E. Shaw & Co's TNGX Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Tango Therapeutics (TNGX) in Q1 2026, closing a stake of 1,025,553 shares — an estimated $9.09M sold.

D.E. Shaw & Co first reported a position in TNGX in Q2 2022 and held it in 8 quarters. The position peaked at $9.09M in Q4 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • D.E. Shaw & Co reported no remaining Tango Therapeutics position as of Q1 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,025,553 Tango Therapeutics shares in Q1 2026, an estimated $9.09M.
  • D.E. Shaw & Co first reported a position in Tango Therapeutics in Q2 2022 and held it in 8 quarters.
  • D.E. Shaw & Co's Tango Therapeutics position peaked at $9.09M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.